Merrill Lynch UK Inv Tst PLC
15 May 2002
MONTHLY PERFORMANCE
MERRILL LYNCH UK INVESTMENT TRUST plc
All information is at 30 April 2002 and unaudited.
Performance at month end with net income reinvested
One Three One Three Five
month months year years years
Net asset value -3.6% -0.5% -20.8% -27.6% 7.7%
Share price -3.7% -5.7% -26.1% -34.8% -2.0%
FTSE All-Share Index -1.6% 1.7% -10.1% -10.8% 33.7%
Sources: Merrill Lynch Investment Managers, Standard & Poor's Micropal
At month end
Net asset value* 878.97p
Share price: 745.00p
Discount: 15.2%
Total assets: £156.8m
Net Yield: 4.0%
Gearing: 33.7%
Effective gearing: 17.7%
Value of debt: £39.5m
Ordinary shares in issue: 13,493,799
*Includes current year net revenue of 10.14p.
UK Sectors % Total Assets
Financials 26.4
Non-Cyclical Consumer Goods 16.9
Cyclical Services 16.3
Resources 12.4
Non-Cyclical Services 8.2
Basic Industries 2.4
General Industrials 2.3
Information Technology 1.8
Utilities 1.3
Cash 12.8
Net current liabilities (0.8)
Total 100.0
Ten Largest Equity Investments
Company
% Investments
BP Amoco 8.8
Barclays 5.5
HSBC 5.3
HBOS 5.2
AstraZeneca 5.2
GlaxoSmithKline 5.2
Royal Bank of Scotland 4.6
Vodafone 4.5
Diageo 3.6
Amersham 3.2
Total 51.1
Market commentary
UK Stockmarket Review
UK equities retreated over the period, with the All-Share Index down 1.6%. The
UK stockmarket received little help from US markets, as strong US GDP data was
overshadowed by weakening industrial confidence and poor corporate newsflow.
Domestic economic data provided little excitement - GDP in the first quarter
rose only 0.1% quarter on quarter. At the sector level, Telecoms shares weighed
greatest on the market, with Mobile shares being sold as investors continued to
question the growth dynamics and profitability of the industry. As concerns over
the health of the global economic recovery and corporate profitability
resurfaced, defensives outperformed the more economically sensitive sectors.
Fund Performance Review
The Company's Net Asset Value (NAV) fell 3.6% during April, underperforming the
FTSE All Share Index, which fell 1.6%.
We suffered from our overweight position in mmO2, which fell as UK Telecoms
shares were hit by profit warnings from their US counterparts. Our choice of
shares in Pharmaceuticals was also negative, as Amersham and AstraZeneca both
disappointed. Amersham fell after first quarter sales were dragged down by
evidence of one-off pricing pressure in the Japanese diagnostics market, while
AstraZeneca was forced by US regulators to delay the launch of Crestor, a key
cholesterol lowering drug.
These events were offset by strong performance in Financials, where our holdings
in Barclays and HBOS performed strongly. Our avoidance of selected cyclical
shares including Cable & Wireless and WPP was also beneficial, as investors
favoured defensive issues.
Outlook
Recent weak headline growth belies starkly divergent trends within the UK
economy. A strong service sector remains underpinned by low interest rates and a
buoyant housing market. This contrasts with a very weak manufacturing sector.
Interest rates are very low even for this stage in the cycle, and while the
broader inflation numbers are subdued, service sector inflation appears to be
more problematic. This implies that the Bank of England will respond quickly to
signs of recovery in the economy. Whilst some sectoral themes may emerge, we
intend to maintain our focus on strong stock ideas where we believe the
stockmarket has underestimated a company's prospects.
Latest information is available by typing www.mlim.co.uk/its on the internet,
'MLIMINDEX' on Reuters, 'MLIM' on Bloomberg or '8800' on Topic 3 (ICV terminal).
15 May 2002
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.